Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANO1 | Q5XXA6 | 16/20 | 1.00 |
| ▸ | ANO2 | Q9NQ90 | 2/20 | 0.84 |
| ▸ | TP53 | P04637 | 4/20 | 0.82 |
| ▸ | MAPT | P10636 | 4/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.82 |
| ▸ | BLM | P54132 | 2/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29601564 | 0.99 | ANO1 (1.00) | ANO1ANO2TP53MAPTSMN1; SMN2 | |
| SCHEMBL29601260 | 0.92 | ANO1 (1.00) | ANO1ANO2TP53MAPTSMN1; SMN2 | |
| SCHEMBL29601541 | 0.91 | ANO1 (1.00) | ANO1ANO2TP53MAPTSMN1; SMN2 | |
| SCHEMBL29601377 | 0.91 | ANO1 (1.00) | ANO1ANO2TP53MAPTSMN1; SMN2 | |
| SCHEMBL4151223 | 0.91 | ANO1 (1.00) | ANO1ANO2TP53MAPTSMN1; SMN2 | |
| SCHEMBL4134799 | 0.91 | ANO1 (1.00) | ANO1ANO2TP53MAPTSMN1; SMN2 | |
| SCHEMBL4136619 | 0.90 | ANO1 (1.00) | ANO1ANO2TP53MAPTSMN1; SMN2 | |
| SCHEMBL20541810 | 0.90 | ANO1 (1.00) | ANO1ANO2TP53MAPTSMN1; SMN2 | |
| SCHEMBL4147246 | 0.90 | ANO1 (0.98) | ANO1ANO2TP53MAPTSMN1; SMN2 | |
| SCHEMBL21853969 | 0.89 | ANO1 (1.00) | ANO1ANO2TP53MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11358947-B2 | Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11358947-B2 | Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A | TMEM161A, ANO2, TRPV6 | ANO1 9/4885ANO2 2/4885TP53 2200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.